Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $3.18
Previous CloseN/A
Volume2.84M
Average Volume (3M)4.66M
Market Cap
$147.36M
Enterprise Value$174.15M
Total Cash (Recent Filing)$12.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Apr 30, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding224,710,020
10 Day Avg. Volume6,260,342
30 Day Avg. Volume4,662,512
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.37
Price to Cash Flow (P/CF)-14.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda-1.90
Forecast
1Y Price Target
$5.00Price Target Upside777.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Partnership OpportunitiesSGMO continues to advance discussions regarding a potential collaboration agreement around the study data.
Regulatory ApprovalThe positive eGFR slope for the first 23 patients is promising and could support potential accelerated approval.
Bears Say
Cash Overhang RiskPFE's decision increases cash overhang risk for SGMO, because the company will no longer be eligible for ~$70M milestone payment for BLA filing.
Program WithdrawalSGMO is down -49% after they announced partner PFE will not file BLA for hemA gene tx.
---
Ownership Overview
2.83% Insiders
12.95% Mutual Funds
7.24% Other Institutional Investors
69.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.30 and its highest was $3.18 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Sangamo Biosciences’s market cap is $147.36M.
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Apr 30, 2025 which is in 28 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Mar 17, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.091 by -$0.019.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -0.09.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 224,710,020 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.091. Following the earnings report the stock price went down -15.842%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Currently, no hedge funds are holding shares in SGMO
---
Sangamo Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (777.19% Upside)
$5.00 (777.19% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 63.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.23%
12-Months-Change
Fundamentals
Return on Equity
-187.83%
Trailing 12-Months
Asset Growth
-36.30%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
---
SGMO Company Deck
---
SGMO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in Sangamo's neurology pipeline and strategic partnerships, along with financial achievements. However, challenges remain in securing a Fabry commercial partner and addressing financing needs, which are critical for future success.Read More>---
SGMO Stock 12 Month Forecast
Average Price Target
$5.00
▲(777.19% Upside)
Technical Analysis
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+19.53%
reiterated a buy rating 2 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +19.53% per trade.
---